These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 30856290)
1. A Dual-Bioresponsive Drug-Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade. Ruan H; Hu Q; Wen D; Chen Q; Chen G; Lu Y; Wang J; Cheng H; Lu W; Gu Z Adv Mater; 2019 Apr; 31(17):e1806957. PubMed ID: 30856290 [TBL] [Abstract][Full Text] [Related]
2. Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy. Chen Q; Chen G; Chen J; Shen J; Zhang X; Wang J; Chan A; Gu Z Nano Lett; 2019 Aug; 19(8):4879-4889. PubMed ID: 31294571 [TBL] [Abstract][Full Text] [Related]
3. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics. Han X; Li H; Zhou D; Chen Z; Gu Z Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988 [TBL] [Abstract][Full Text] [Related]
4. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma. Zhang N; Song J; Liu Y; Liu M; Zhang L; Sheng D; Deng L; Yi H; Wu M; Zheng Y; Wang Z; Yang Z J Control Release; 2019 Jul; 306():15-28. PubMed ID: 31132380 [TBL] [Abstract][Full Text] [Related]
5. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles. Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231 [TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
7. A tumor microenvironment responsive biodegradable CaCO Liu Y; Pan Y; Cao W; Xia F; Liu B; Niu J; Alfranca G; Sun X; Ma L; de la Fuente JM; Song J; Ni J; Cui D Theranostics; 2019; 9(23):6867-6884. PubMed ID: 31660074 [TBL] [Abstract][Full Text] [Related]
8. Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade. Yu S; Wang C; Yu J; Wang J; Lu Y; Zhang Y; Zhang X; Hu Q; Sun W; He C; Chen X; Gu Z Adv Mater; 2018 Jul; 30(28):e1801527. PubMed ID: 29786888 [TBL] [Abstract][Full Text] [Related]
9. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Woods DM; Sodré AL; Villagra A; Sarnaik A; Sotomayor EM; Weber J Cancer Immunol Res; 2015 Dec; 3(12):1375-85. PubMed ID: 26297712 [TBL] [Abstract][Full Text] [Related]
10. Enhanced Osteosarcoma Immunotherapy via CaCO Gao Y; Wang Z; Jin X; Wang X; Tao Y; Huang S; Wang Y; Hua Y; Guo X; Xu J; Cai Z Adv Healthc Mater; 2024 Sep; 13(23):e2400538. PubMed ID: 38759954 [TBL] [Abstract][Full Text] [Related]
11. Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy. Zhao P; Qiu L; Zhou S; Li L; Qian Z; Zhang H Int J Nanomedicine; 2021; 16():2107-2121. PubMed ID: 33737808 [TBL] [Abstract][Full Text] [Related]
12. Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody. Wang C; Ye Y; Hochu GM; Sadeghifar H; Gu Z Nano Lett; 2016 Apr; 16(4):2334-40. PubMed ID: 26999507 [TBL] [Abstract][Full Text] [Related]
13. Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanoma. Kuang X; Wang Z; Luo Z; He Z; Liang L; Gao Q; Li Y; Xia K; Xie Z; Chang R; Wang Y; Liu Y; Zhao S; Su J; Wang Y; Situ W; Chen M; Zhao Y; Chen X; Xie H; Liu H J Colloid Interface Sci; 2022 Jun; 616():189-200. PubMed ID: 35203032 [TBL] [Abstract][Full Text] [Related]
14. Bioresponsive and immunotherapeutic nanomaterials to remodel tumor microenvironment for enhanced immune checkpoint blockade. Fang T; Cao X; Wang L; Chen M; Deng Y; Chen G Bioact Mater; 2024 Feb; 32():530-542. PubMed ID: 38026439 [TBL] [Abstract][Full Text] [Related]
15. Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody. Tej GNVC; Neogi K; Nayak PK Int Immunopharmacol; 2019 Dec; 77():106002. PubMed ID: 31711939 [TBL] [Abstract][Full Text] [Related]
16. Biodegradable pH-responsive amorphous calcium carbonate nanoparticles as immunoadjuvants for multimodal imaging and enhanced photoimmunotherapy. Wang M; Zhou B; Wang L; Zhou F; Smith N; Saunders D; Towner RA; Song J; Qu J; Chen WR J Mater Chem B; 2020 Sep; 8(36):8261-8270. PubMed ID: 32812632 [TBL] [Abstract][Full Text] [Related]
17. [Immune checkpoint‑targeted cancer immunotherapies]. Swatler J; Kozłowska E Postepy Hig Med Dosw (Online); 2016 Jan; 70():25-42. PubMed ID: 26864062 [TBL] [Abstract][Full Text] [Related]
18. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. Vijayakumar G; McCroskery S; Palese P J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938 [TBL] [Abstract][Full Text] [Related]
19. Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth. Kwak G; Kim D; Nam GH; Wang SY; Kim IS; Kim SH; Kwon IC; Yeo Y ACS Nano; 2017 Oct; 11(10):10135-10146. PubMed ID: 28985469 [TBL] [Abstract][Full Text] [Related]
20. Intratumoral delivery of M-CSF by calcium crosslinked polymer micelles enhances cancer immunotherapy. Mao K; Cong X; Feng L; Chen H; Wang J; Wu C; Liu K; Xiao C; Yang YG; Sun T Biomater Sci; 2019 Jun; 7(7):2769-2776. PubMed ID: 31012882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]